supplied by www.ccc.ac.at

9 Einträge

Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
Autoren Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RB, Kirnbauer R
Erscheinungsdaten The Journal of investigative dermatology. 2013 May 10. pii: jid2013253. doi: 10.1038/jid.2013.253. pmc: PMC3826974. mid: EMS54966
Publikations ID PMID: 23752042
 


Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes.
Autoren Shafti-Keramat S, Schellenbacher C, Handisurya A, Christensen N, Reininger B, Brandt S, Kirnbauer R
Erscheinungsdaten Virology. 2009 Sep 3. pii: S0042-6822(09)00474-7. doi: 10.1016/j.virol.2009.07.036. pmc: PMC3792341. mid: EMS54975
Publikations ID PMID: 19729180
 


Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells.
Autoren Handisurya A, Gilch S, Winter D, Shafti-Keramat S, Maurer D, Schätzl HM, Kirnbauer R
Erscheinungsdaten The FEBS journal. 2007 Feb 20. pii: EJB5721. doi: 10.1111/j.1742-4658.2007.05721.x. pmc: PMC3792370. mid: EMS54972
Publikations ID PMID: 17313482
 


A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Autoren Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R
Erscheinungsdaten Vaccine. 2006 Nov 29. pii: S0264-410X(06)01255-2. doi: 10.1016/j.vaccine.2006.11.049. pmc: PMC3935451. mid: EMS54968
Publikations ID PMID: 17239496
 


Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors.
Autoren Schellenbacher C, Shafti-Keramat S, Huber B, Fink D, Brandt S, Kirnbauer R
Erscheinungsdaten Virology. 2015 Oct 28. pii: S0042-6822(15)00373-6. doi: 10.1016/j.virol.2015.08.016
Publikations ID PMID: 26519597
 


Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Autoren Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R
Erscheinungsdaten PloS one. 2017 Jan 5. doi: 10.1371/journal.pone.0169533. pii: PONE-D-16-41348
Publikations ID PMID: 28056100
 


Type-specific L1 virus-like particle-mediated protection of horses from experimental bovine papillomavirus 1-induced pseudo-sarcoid formation is long-lasting.
Autoren Harnacker J, Hainisch EK, Shafti-Keramat S, Kirnbauer R, Brandt S
Erscheinungsdaten The Journal of general virology. 2017 Jun 21. doi: 10.1099/jgv.0.000791
Publikations ID PMID: 28635592
 


Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation.
Autoren Hartl B, Hainisch EK, Shafti-Keramat S, Kirnbauer R, Corteggio A, Borzacchiello G, Tober R, Kainzbauer C, Pratscher B, Brandt S
Erscheinungsdaten The Journal of general virology. 2011 Jun 29. doi: 10.1099/vir.0.033670-0. pmc: PMC5034893. mid: EMS55129
Publikations ID PMID: 21715602
 


Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice.
Autoren Zamora E, Handisurya A, Shafti-Keramat S, Borchelt D, Rudow G, Conant K, Cox C, Troncoso JC, Kirnbauer R
Erscheinungsdaten Journal of immunology (Baltimore, Md. : 1950). 2006 Aug 4. pmc: PMC3792340. mid: EMS54974
Publikations ID PMID: 16888028